• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BARDA awards Novan $7.8 million contract

BARDA awards Novan $7.8 million contract

August 27, 2013
CenterWatch Staff

The U.S. Department of Health and Human Services has entered into a contract with Novan, a clinical-stage drug development company focused on topical delivery of nitric oxide, to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. 

The Biomedical Advanced Research and Development Authority (BARDA), an agency within the Office of the Assistant Secretary for Preparedness and Response, awarded this contract. It is believed a mass casualty event caused by natural or intentional threats to public health could result in tens of thousands of burn patients, which would overwhelm the burn care infrastructure available in hospitals across the U.S. 

BARDA will provide $7.8 million in funding over two years. The contract will support the pharmaceutical development of the Nitric Oxide Advanced Healing (NOAH) technology including formulation work, nonclinical toxicology and proof of concept studies in models of deep partial thickness and full thickness thermal injuries. This project is designed to enable the future clinical investigation of the medical countermeasure.

"The link between nitric oxide and the body's ability to heal is well established,” said Nathan Stasko, president of Novan.  “The challenge is to create stable nitric oxide drugs that 'perform on command' and deliver a controlled, sustained dose that will supplement the body's ability to regenerate tissue. Our platform technology has allowed us to pursue the development of drugs intended to harness the healing power of nitric oxide with results extending beyond bioterrorism. We believe the NOAH technology creates a gateway into regenerative medicine and could lead to therapies that can help heal both acute and chronic wounds."

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing